Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do babies perceive cries as speech?

Developmental cognitive neuroscience·2026
Same author

IL-10-neutralising autoantibodies in paediatric-onset inflammatory bowel disease.

Gut·2026
Same author

The anatomical type of atresia drives the risk of home parenteral nutrition of infants with congenital jejunoileal atresia.

European journal of pediatrics·2026
Same author

Readmission and Late Mortality Among Children With Congenital Diaphragmatic Hernia.

JAMA network open·2026
Same author

Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults.

Inflammatory bowel diseases·2026
Same author

Bovine colostrum as a human milk fortifier: promising biology, elusive clinical benefit.

Pediatric research·2026

Related Experiment Video

Updated: Sep 5, 2025

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.8K

Mitchell-Riley Syndrome: Improving Clinical Outcomes and Searching for Functional Impact of RFX-6 Mutations.

Caroline de Gouveia Buff Passone1,2, Gaëlle Vermillac2, Willem Staels1,3,4

  • 1Department of Endocrinology, Metabolism and Diabetes, Inserm U1016, Cochin Institute, Paris, France.

Frontiers in Endocrinology
|July 11, 2022
PubMed
Summary

Mitchell-Riley syndrome (MRS) management improved outcomes in four new cases. Mutations in the RFX6 gene impair pancreatic beta-cell function, highlighting the need for advanced diabetes technologies and further research into enteroendocrine system modulation.

Keywords:
Mitchell–Riley syndromeRFX6beta-cell functiondiabetes technologyneonatal diabetes mellitusparenteral nutrition

More Related Videos

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

8.0K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Related Experiment Videos

Last Updated: Sep 5, 2025

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.8K
A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

8.0K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Area of Science:

  • Genetics
  • Endocrinology
  • Developmental Biology

Background:

  • Mitchell-Riley syndrome (MRS) is a rare genetic disorder caused by biallelic mutations in the RFX6 gene.
  • MRS presents with severe neonatal complications including diabetes, pancreatic hypoplasia, and gastrointestinal anomalies.
  • Previous reports indicate a poor prognosis for affected individuals.

Purpose of the Study:

  • To describe the multidisciplinary intensive clinical management of four new cases of MRS.
  • To investigate the functional impact of specific RFX6 mutations on gene expression.
  • To explore potential therapeutic strategies for MRS.

Main Methods:

  • Detailed analysis of clinical records from four MRS patients.
  • Assessment of RFX6 variants (R181W and V506G) for their ability to transactivate insulin and L-type calcium channel genes.
  • Implementation of advanced diabetes management technologies.

Main Results:

  • All four patients exhibited small for gestational age (SGA) status and duodenal atresia, with early-onset neonatal diabetes.
  • Patients required intensive insulin therapy, including sensor-augmented insulin pump therapy with predictive low-glucose suspension.
  • RFX6 mutations (R181W, V506G) impaired the transactivation of insulin and L-type calcium channel genes, crucial for pancreatic beta-cell function.

Conclusions:

  • Intensive, multidisciplinary management, including advanced diabetes technology, improved clinical outcomes in MRS patients.
  • Understanding RFX6 function in intestinal and pancreatic cells is key to developing novel therapies.
  • Modulating the enteroendocrine system may offer new therapeutic avenues for MRS.